Achilles Therapeutics Company

Achilles Therapeutics’ aims to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. The company is headquartered in London, UK and was launched in May 2016.
Technology: Cell Therapies
Industry: Personalized Medicine
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 2016
Employees Number: Undisclosed
Funding Status: Seed

Visit Website
Register and Claim Ownership